[go: up one dir, main page]

NO994778D0 - FremgangsmÕter og sammensetninger for behandling av tarmbetennelse - Google Patents

FremgangsmÕter og sammensetninger for behandling av tarmbetennelse

Info

Publication number
NO994778D0
NO994778D0 NO994778A NO994778A NO994778D0 NO 994778 D0 NO994778 D0 NO 994778D0 NO 994778 A NO994778 A NO 994778A NO 994778 A NO994778 A NO 994778A NO 994778 D0 NO994778 D0 NO 994778D0
Authority
NO
Norway
Prior art keywords
compositions
treatment
methods
intestinal inflammation
intestinal
Prior art date
Application number
NO994778A
Other languages
English (en)
Other versions
NO994778L (no
NO325947B1 (no
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of NO994778D0 publication Critical patent/NO994778D0/no
Publication of NO994778L publication Critical patent/NO994778L/no
Publication of NO325947B1 publication Critical patent/NO325947B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19994778A 1997-04-01 1999-09-30 Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. NO325947B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (3)

Publication Number Publication Date
NO994778D0 true NO994778D0 (no) 1999-09-30
NO994778L NO994778L (no) 1999-11-30
NO325947B1 NO325947B1 (no) 2008-08-25

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994778A NO325947B1 (no) 1997-04-01 1999-09-30 Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom.

Country Status (16)

Country Link
US (1) US6277836B1 (no)
EP (1) EP0971735B1 (no)
JP (3) JP2001524951A (no)
AR (1) AR012304A1 (no)
AT (1) ATE389417T1 (no)
CA (1) CA2285923C (no)
CY (1) CY1109783T1 (no)
DE (1) DE69839261T2 (no)
DK (1) DK0971735T3 (no)
ES (1) ES2303351T3 (no)
IL (1) IL132145A (no)
NO (1) NO325947B1 (no)
NZ (1) NZ500696A (no)
PT (1) PT971735E (no)
SI (1) SI0971735T1 (no)
WO (1) WO1998043667A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
JP2002536404A (ja) * 1999-02-12 2002-10-29 ワシントン ユニバーシティー 炎症性腸疾患を治療するための好中球機能の刺激
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
NZ521368A (en) * 2000-03-28 2004-05-28 Biochemie Ges M Granulated particles of an active compound, with a film-forming coating resulting in the masked taste of said active compound
AU2001285311B2 (en) 2000-08-29 2005-09-15 Biocon, Ltd Immunoregulatory compounds, derivatives thereof and their use
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
AU2004314731B2 (en) * 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
NZ549661A (en) 2004-02-06 2010-07-30 Pharmatel R & D Pty Ltd As Tru Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
KR101299399B1 (ko) 2004-06-04 2013-08-22 아피늄 파마슈티컬스, 인크. 치료제, 및 그의 제조 및 사용 방법
US7932366B2 (en) 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN103948609A (zh) * 2005-08-24 2014-07-30 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
WO2009047801A1 (en) * 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
TR201819940T4 (tr) * 2008-02-08 2019-01-21 Red Hill Biopharma Ltd Enflamatuar bağırsak hastalığının tedavisi için yöntemler ve bileşimler.
MX2010011995A (es) * 2008-05-01 2010-12-02 Procter & Gamble Metodos y estuches para el tratamiento de condiciones y trastornos inflamatorios del intestino.
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
EP2493471B1 (en) 2009-10-26 2019-11-27 Thomas Julius Borody Novel enteric combination therapy
US8497256B2 (en) 2010-04-26 2013-07-30 Salix Pharmaceuticals, Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
MX355760B (es) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
BR122021020778B1 (pt) 2012-06-19 2022-07-12 Debiopharm International Sa Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
JP6454640B2 (ja) 2012-07-27 2019-01-16 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． 結腸排出促進における使用のための製剤および製剤製造方法
CN110693905A (zh) * 2014-05-22 2020-01-17 约翰·托德·金斯特纳 使用紫外线血液辐照和抗生素的组合治疗疾病
SI3419628T1 (sl) 2016-02-26 2021-03-31 Debiopharm International Sa Zdravilo za zdravljenje infekcij diabetičnega stopala
PH12021551922A1 (en) 2019-02-14 2022-05-23 Debiopharm Int Sa Afabicin formulation, method for making the same
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
AU2021298936A1 (en) 2020-06-30 2023-01-19 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
NO994778L (no) 1999-11-30
JP2008024713A (ja) 2008-02-07
DE69839261T2 (de) 2009-03-26
PT971735E (pt) 2008-06-02
EP0971735A4 (en) 2004-02-25
CA2285923A1 (en) 1998-10-08
AR012304A1 (es) 2000-10-18
EP0971735A1 (en) 2000-01-19
DK0971735T3 (da) 2008-07-07
CA2285923C (en) 2013-03-12
ATE389417T1 (de) 2008-04-15
JP2012126736A (ja) 2012-07-05
NO325947B1 (no) 2008-08-25
CY1109783T1 (el) 2013-09-04
ES2303351T3 (es) 2008-08-01
JP2001524951A (ja) 2001-12-04
EP0971735B1 (en) 2008-03-19
IL132145A0 (en) 2001-03-19
DE69839261D1 (de) 2008-04-30
SI0971735T1 (sl) 2008-08-31
IL132145A (en) 2005-11-20
US6277836B1 (en) 2001-08-21
WO1998043667A1 (en) 1998-10-08
NZ500696A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO982311D0 (no) Sammensetninger og fremgangsmÕter for forhindring og behandling av oral mukositt
NO20003096L (no) Sammensetninger og fremgangsmÕter for behandling av ADD
NO992641D0 (no) Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer
NO971015L (no) Forbindelser og metoder for behandling av cancer
LV11865A (lv) Kompozicijas un panemieni tuklo sunu iekaisumu arstesanai
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
DK1003479T3 (da) Fremgangsmåde og sammensætninger til behandling af allergiske senfasereaktioner og inflammatoriske sygdomme
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
NO972972D0 (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
NO984094D0 (no) Utladningsreaktor og anvendelse av samme
NO985484D0 (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
IS4805A (is) Aðferð til meðhöndlunar og lyfjasamsetning
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
BR9709450A (pt) Inibidores de produção do s-cd23 e da secreção de tnt
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
NO983512D0 (no) Midler for behandling og forhindring av AIDS
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
NO20021832D0 (no) Farmasöytiske sammensetninger av tizoksanid og nitazoksanid
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO20012099D0 (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- carbinoler og beslektede forbindelser
NO990018D0 (no) Belegg og fremgangsmÕte for fremstilling derav

Legal Events

Date Code Title Description
MK1K Patent expired